Is AMGN a good stock to buy?
Amgen Inc. · end-of-day data as of Nov 13, 2026
- P/E vs sector-16.2%
- Trendbullish
- MAs4 of 4
- Sector▲ +15.9%
- Earnings in81d
- P/E27.0x
- RSI62
- Support-4.7%
- Off 52w high-3.8%
- Volume0.6x
- Bollingerupper half
- News2.00
- FCF yield+3.8%
- ConsensusHold · 35
- 52w range$312–$484
- ATR+2.5%
- Off ATH-3.8%
- InsidersNone in 90d
- PT$423.13 -9.1%
- P/E vs own+14.4%
- MACD-0.70
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Amgen a good stock to buy?
Amgen is strong on 3 of the 5 questions about the business. The price is about usual: 27.0 times its earnings, near its 3-year median of 24.5 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage some edge
- Economics profits growing
- Execution delivers
- Fragility some risks
- Price about usual
AMGN sales growth revenue growth
+12%a year, for the last 3 yearsAmgen's sales grew 12% a year for 3 years, to $36.77B in fiscal 2025.
AMGN analysts' forecast revenue estimates
+7%the sales they expect next fiscal year, on the lastAnalysts expect Amgen's sales to grow 7% to $39.43B in fiscal 2026 (22 analysts).
AMGN competitors
pretickt analysis+8%its sales in 12 months, on a year before
Amgen's sales grew 8% in the 12 months to Sep 30, 2026, faster than Gilead (+7%), Merck (+5%), Bristol-Myers Squibb (+4%) and Pfizer (+1%).
AMGN customers' spending
pretickt analysis+23%what its customers invest, on a year before
Cencora, Cardinal Health and McKesson, customers of Amgen, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.
AMGN sales by business revenue by segment
21%of its sales from Other ProductsOther Products brought Amgen 21% of its sales in fiscal 2025; Prolia 12%.
AMGN margin on each sale gross margin
74%left after making the productAmgen kept 74% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 75%.
AMGN cash generated free cash flow
$9.58Bcash left after investing, last 12 monthsAmgen generated $9.58B of free cash flow in the 12 months to Sep 30, 2026, about as much as its reported profit.
AMGN earnings vs estimates
8 of 8quarters above the analysts' estimateAmgen beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 3, 2026.
AMGN insider selling
-$13.02Msold, net, by its executives in 12 monthsAmgen's executives and directors sold a net $13.02M of shares in the 12 months to Nov 13, 2026; none bought.
AMGN number of employees
+13%more people in a yearAmgen had 31,500 employees at the end of fiscal 2025, 13% more than a year before.
AMGN CEO pay
$24.69Mfor fiscal 2025, 73% of it in stock and optionsAmgen paid its CEO $24.69M for fiscal 2025, 73% of it in stock and options.
AMGN financial health Altman Z-score
2.6Altman Z-score, safe above 3Amgen's Altman Z-score is 2.6 (Nov 13, 2026), between 1.8 and 3, the grey zone.
AMGN quality checks Piotroski score
8 of 9checks passedAmgen passes 8 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on new shares.
AMGN biggest customers
77%of sales from its 3 biggest customersMcKesson, Cencora and Cardinal Health made 77% of Amgen's sales in fiscal 2025.
AMGN in past recessions
pretickt analysis-2%its sales in the worst oneAmgen's sales fell in 1 of the last 2 US recessions, by as much as 2% in fiscal 2009.
AMGN price vs profit P/E ratio
27.0×a year's earningsAmgen's P/E ratio is 27.0 (Nov 13, 2026), near its 3-year median of 24.5.
AMGN price vs competitors
pretickt analysis27.0×a year's earnings, against its competitorsInvestors pay 27.0 times Amgen's earnings (Nov 13, 2026), more than for Bristol-Myers Squibb (14.1), less than for Merck (152.3) and Pfizer (41.5).
AMGN analysts' target price target
-9%to their average targetAnalysts' average price target for Amgen is $423, 9% below the Nov 13, 2026 close of $465.67.
AMGN analyst ratings, 90 days
pretickt analysisBMO Capitaldowngrade HSBCdowngrade Freedom Brokerdowngrade
In the 90 days to Nov 13, 2026, BMO Capital, HSBC and Freedom Broker downgraded Amgen.
AMGN growth priced in fair value
pretickt analysis+11%a year, for ten years, to be worth the priceAt $465.67 a share, Amgen's free cash flow must grow about 11% a year for ten years to be worth the price (Nov 13, 2026).
What is Amgen's P/E ratio?
Amgen's P/E ratio is 27.0 (Nov 13, 2026), near its 3-year median of 24.5. Investors pay 27.0 times Amgen's earnings (Nov 13, 2026), more than for Bristol-Myers Squibb (14.1), less than for Merck (152.3) and Pfizer (41.5).
Who are Amgen's biggest competitors?
pretickt compares Amgen with Gilead, Merck, Pfizer and Bristol-Myers Squibb. Amgen's sales grew 8% in the 12 months to Sep 30, 2026, faster than Gilead (+7%), Merck (+5%), Bristol-Myers Squibb (+4%) and Pfizer (+1%).
Are insiders selling Amgen stock?
Amgen's executives and directors sold a net $13.02M of shares in the 12 months to Nov 13, 2026; none bought.
How does Amgen make money?
Other Products brought Amgen 21% of its sales in fiscal 2025; Prolia 12%.
Who owns Amgen stock?
3,261 institutions hold 86% of Amgen's shares (Jun 30, 2026); Vanguard, BlackRock and State Street added shares that quarter.
How many employees does Amgen have?
Amgen had 31,500 employees at the end of fiscal 2025, 13% more than a year before.
Who are Amgen's biggest customers?
McKesson, Cencora and Cardinal Health made 77% of Amgen's sales in fiscal 2025. Cencora, Cardinal Health and McKesson, customers of Amgen, spent 23% more on capital in their latest quarter (to Sep 30, 2026) than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.